Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicinesDesignation granted for warm autoimmune hemolytic anemia and IgG4-related…Read More
You might also be interested in reading ‘Debasement trade’ is no longer a debate, and TradFi knows it: Execs.